Merck & Co., Inc.

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 7, 2026), Merck & Co., Inc. reported 13 stock positions worth $526.4 million. Its top holding was Personalis (PSNL) at 35.8% of the portfolio, followed by Moderna (MRNA, 30.7%) and Kymera Therapeutics (KYMR, 16.8%). Compared with Q1 2026, it opened 3 new positions and sold out of 4. The biggest buy was a new position in Entrada Therapeutics (TRDA) and the biggest sale an exit from Entrada Therapeutics.

Most Recent 13F
Q2 2026
Location
RAHWAY, NJ
CIK
0000310158
Portfolio Value
$526.4M (Q2 2026)
SEC Filing
0000310158-26-000210 ↗ filed Aug 7, 2026

Holdings Value

0$200.0M$400.0M$600.0M Q4 2024: $258.0M Q4 2024 Q1 2025: $164.3M Q1 2025 Q2 2025: $215.6M Q2 2025 Q3 2025: $228.0M Q3 2025 Q4 2025: $276.3M Q4 2025 Q1 2026: $349.4M Q1 2026 Q2 2026: $526.4M $526.4M Q2 2026

Holdings 13 stocks · $526.4M
PSNL Personalis Inc. 35.75% 14,044,943 $188.2M No change
MRNA Moderna Inc. 30.71% 2,308,190 $161.6M No change
KYMR Kymera Therapeutics Inc. 16.82% 772,165 $88.5M No change
AKTS Aktis Oncology Inc. 5.83% 952,844 $30.7M No change
EIKN Eikon Therapeutics Inc. 4.13% 1,666,666 $21.7M No change
TRDA Entrada Therapeutics Inc. 2.43% 1,739,768 $12.8M New
STRO Sutro Biopharma Inc. 1.72% 272,351 $9.0M New
ALEC Alector Inc. 1.35% 3,545,719 $7.1M No change
EVAX Evaxion A/S 0.71% 1,214,126 $3.8M New
VRDN Viridian Therapeutics Inc. 0.33% 93,414 $1.7M No change
XLO Xilio Therapeutics Inc. 0.19% 105,982 $1.0M No change
HURA Tuhura Biosciences Inc. 0.01% 19,445 $46K No change
NEUP Neuphoria Therapeutics Inc. 0.01% 10,027 $44K No change

Portfolio Sells Q1 2026 → Q2 2026
ENTRADA THERAPEUTICS INC Sold out 0.00% −6.28
STRO Sutro Biopharma Inc. Com SHS Sold out 0.00% −1.94
EVAX Evaxion Biotech A/S Sold out 0.00% −1.29
CARM Carisma Therapeutics Inc. Sold out 0.00% −0.01

Portfolio Buys Q1 2026 → Q2 2026
TRDA Entrada Therapeutics Inc. New 2.43% +2.43
STRO Sutro Biopharma Inc. New 1.72% +1.72
EVAX Evaxion A/S New 0.71% +0.71

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 13$526.4MPSNL, MRNA, KYMR, AKTS, EIKN
Q1 2026 14$349.4MMRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, EIKN
Q4 2025 12$276.3MPSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, EVAX
Q3 2025 13$228.0MPSNL, MRNA, KYMR, ALEC, ENTRADA THERAPEUTICS INC
Q2 2025 13$215.6MPSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, ALEC
Q1 2025 12$164.3MMRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC
Q4 2024 13$258.0MMRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC